ReviewInfectious medicine2023
Monkeypox virus (MPXV): A Brief account of global spread, epidemiology, virology, clinical features, pathogenesis, and therapeutic interventions.
Review in Infectious medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Mpox vaccine acceptance and uptake in Africa: a systematic review and meta-analysis.BMC global and public health · 2026Pooled it
- Virtual Screening of Bacteriocins From Lactic Acid Bacteria Against Monkeypox DNA Polymerase: Sakacin P and Mundticin KS Emerge as Promising Candidates.Food science & nutrition · 2026Article
- Targeting Zoonotic Spillover Drivers for Global Pandemic Prevention: A Narrative Review.Microorganisms · 2026Review
- A Novel Monoclonal Antibody Targeting the A29 Protein of Monkeypox Virus and Its Application in Immunoassay.Antibodies (Basel, Switzerland) · 2026Article
- Therapeutic Innovations for Monkeypox Inhibition.International journal of molecular sciences · 2026Review
- Article
- Review
- First Comprehensive Global Bibliometric Analysis of Monkeypox Virus Research Landscape From 1976 to 2025.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026Article
- Review
- Monkeypox Virus Countermeasures: Vaccines, Antibodies, Drugs and Traditional Chinese Medicine.Drug design, development and therapy · 2026Review
- Emerging threats of monkeypox virus in 2024: current insights and future directions.Future science OA · 2025Review
- A metagenomic approach for microbial risk assessment and source attribution in high-risk ports of entry environments.Biosafety and health · 2025Article
- Novel drug targets for monkeypox: From viral to host proteins.Infectious medicine · 2025Article
- Personalized immunization against Mpox Clades I and Ib: Strategies to combat the emerging epidemic.Infectious medicine · 2025Review
- From pox to protection: understanding Monkeypox pathophysiology and immune resilience.Tropical medicine and health · 2025Review
- Transcriptomic and Proteomic Analysis of Monkeypox Virus A5L-Expressing HEK293T Cells.International journal of molecular sciences · 2025Article
- Virology, epidemiology, transmissions, diagnostic tests, prophylaxis and treatments of human Mpox: Saudi Arabia perspective.Frontiers in cellular and infection microbiology · 2025Review
- Mpox: An emerging or re-emerging infection with a potential colossal burden on healthcare globally.African journal of laboratory medicine · 2025Review
- The resurgence of monkeypox virus: a critical global health challenge and the need for vigilant intervention.Frontiers in public health · 2025Review
- Assessment of knowledge and awareness of monkeypox viral infection in Palestine: a community-based study.Frontiers in cellular and infection microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The largest monkeypox virus (MPXV) outbreak of the 21st century occurred in 2022, which caused epidemics in many countries. According to WHO, physical contact with infected persons, contaminated surfaces, or affected animals might be a source of this virus transmission. A febrile sickness including few symptoms found in MPX disease. Skin rash, lesions, fever, headache, fatigue, and muscle aches symptoms were observed commonly for this disease. Animal and in vitro, studies have shown that the antiviral medications cidofovir and brincidofovir are effective against MPXV. The first-generation vaccinia virus vaccine was developed in 1960, and it helped to protect against MPXV with its side effects. A second-generation vaccination with limitations was launched in 2000. However, the CDC advised vaccinations for risk groups in endemic countries, including positive patients and hospital employees. The JYNNEOS vaccine, administered in 2 doses, also provides protection from MPX. This article presents concisely the most recent findings regarding epidemiology, genomic transmission, signs and symptoms, pathogenesis, diagnosis, and therapeutic interventions for MPXV, which may be helpful to researchers and practitioners. WHO declared that MPX was no longer a global health emergency due to its declining case rate, and a number of countries have reported new incidences. Further research-based investigations must be carried out based on the 2022 outbreak.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.